Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05481697 · ClinicalTrials.gov registry record · NA
Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combin
A NA study of Unintended Weight Loss, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT05481697: Recruiting NA study of Unintended Weight Loss, sponsored by Case Comprehensive Cancer Center.
NCT05481697 is a NA study of Unintended Weight Loss that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05481697, a NA study of Unintended Weight Loss, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. This study aims to test the potential synergistic effects of UWL detection and GRAIL usage to detect malignancy at an even earlier rate. UWL will be measured using weekly weight tracking.
Primary Outcome
High-risk participant cohorts who have lost greater than or equal to 5% of their body weight at initial enrollment over the 3-year weight measuring period will be given a GRAIL Galleri test. If positive, the participant will be given laboratory work, imaging, and a physical examination to diagnose the malignancy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST GRAIL Galleri
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2027-01-01 |
| Phase | NA |
What NCT05481697 shows while recruiting
NCT05481697 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Unintended Weight Loss appearing as the primary indexed condition, and to 1 intervention - of which GRAIL Galleri is the first listed.
NCT05481697 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05481697 about?
NCT05481697 is a clinical study titled "Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combin". Unintentional weight loss (UWL) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating UWL. When detecting UWL coupled with GRAIL Galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater...
What is the current status of trial NCT05481697?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2023-05-05. Estimated completion is 2027-01-01.
What conditions does trial NCT05481697 study?
This clinical trial studies the following conditions: Unintended Weight Loss.
What interventions are being tested in trial NCT05481697?
The interventions under investigation include: GRAIL Galleri (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05481697?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05481697 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05481697's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI